Cryptenamine Acetates

CHEMBL1201444 Phase 4 Zugelassen Unknown

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

A combination preparation containing alkaloids that lower blood pressure by acting on the nervous system and blood vessels. It has been used to treat hypertension.

Therapeutische Bereiche

Neurology Hypertension

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A combination preparation containing alkaloids that lower blood pressure by acting on the nervous system and blood vessels. It has been used to treat hypertension.

Yes, Cryptenamine Acetates is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201444. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Cryptenamine Acetates auf PillFYI

Schnelldaten

Externe Links

ChEMBL CHEMBL1201444

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.